老年弥漫大B细胞淋巴瘤一线治疗进展

Advances in the first-line therapy of elderly patients with diffuse large B-cell lymphoma

摘要:

老年弥漫大B细胞淋巴瘤（DLBCL）患者较年轻患者预后差，这与该人群未能接受标准治疗，以及疾病本身的不良生物学特征相关。尽管R-CHOP方案（利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松）是治疗老年DLBCL的一线标准，但还需结合患者的年龄、治疗耐受性、分子生物学特征、危险分层等因素综合考虑。目前老年DLBCL患者中的一线改良方案多以R-CHOP方案为基础，不断尝试添加新药单药或联合化疗，以提高该人群治疗的安全性和有效率。

Abstract:

Elderly patients with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients. It might be associated with the failure to receive standard care in these patients and the adverse biological characteristics of the disease. The R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen is the standard first-line therapy for DLBCL. However, multiple factors such as the age of patients, the tolerance to the treatment, the molecular biological characteristics, and the risk stratification should also be considered. Currently, the modified first-line therapeutic strategies for the elderly patients with DLBCL were mostly based on the R-CHOP regimen with the addition of a single drug or chemotherapy, aiming to improve the safety and efficacy of the treatment.